Drug screening for ALS using patient-specific induced pluripotent stem cells.
about
The conditional KO approach: Cre/Lox technology in human neuronsAnalysis of conditional heterozygous STXBP1 mutations in human neuronsDysregulated axonal RNA translation in amyotrophic lateral sclerosisThe Use of Stem Cells to Model Amyotrophic Lateral Sclerosis and Frontotemporal Dementia: From Basic Research to Regenerative MedicineFunctional Evaluations of Genes Disrupted in Patients with Tourette's Disorder.Induced pluripotent stem cells for modeling neurological disordersEpigenetic Research of Neurodegenerative Disorders Using Patient iPSC-Based ModelsGolgi Fragmentation in ALS Motor Neurons. New Mechanisms Targeting Microtubules, Tethers, and Transport VesiclesALS Patient Stem Cells for Unveiling Disease Signatures of Motoneuron Susceptibility: Perspectives on the Deadly Mitochondria, ER Stress and Calcium TriadAn Overview of Direct Somatic Reprogramming: The Ins and Outs of iPSCsModeling ALS and FTD with iPSC-derived neuronsImportance of being Nernst: Synaptic activity and functional relevance in stem cell-derived neuronsApplications of Induced Pluripotent Stem Cells in Studying the Neurodegenerative DiseasesInduced pluripotent stem cell technology for dissecting the cancer epigenomeAdvancements in stem cells treatment of skeletal muscle wastingCutting-edge microfabricated biomedical tools for human pluripotent stem cell researchInduction of pluripotency by defined factorsiPSC-Based Models to Unravel Key Pathogenetic Processes Underlying Motor Neuron Disease DevelopmentTherapeutic and diagnostic challenges for frontotemporal dementiaInduced pluripotent stem cells from ALS patients for disease modelingModeling Huntington's disease with induced pluripotent stem cellsHuman pluripotent stem cells for modelling human liver diseases and cell therapyNeurodegenerative diseases in a dish: the promise of iPSC technology in disease modeling and therapeutic discoveryPathways disrupted in human ALS motor neurons identified through genetic correction of mutant SOD1.Cell-based screening: extracting meaning from complex data.Recent Advances and the Future of Stem Cell Therapies in Amyotrophic Lateral SclerosisCommon pitfalls of stem cell differentiation: a guide to improving protocols for neurodegenerative disease models and researchA perspective on stem cell modeling of amyotrophic lateral sclerosisUtilizing induced pluripotent stem cells (iPSCs) to understand the actions of estrogens in human neuronsInduced Pluripotent Stem Cell Models to Enable In Vitro Models for Screening in the Central Nervous SystemA comprehensive library of familial human amyotrophic lateral sclerosis induced pluripotent stem cellsA system for studying mechanisms of neuromuscular junction development and maintenanceStem cells and modeling of autism spectrum disorders.Astrocyte pathology and the absence of non-cell autonomy in an induced pluripotent stem cell model of TDP-43 proteinopathy.A high-content screen identifies novel compounds that inhibit stress-induced TDP-43 cellular aggregation and associated cytotoxicity.Statistical analysis of dendritic spine distributions in rat hippocampal cultures.Withania somnifera Reverses Transactive Response DNA Binding Protein 43 Proteinopathy in a Mouse Model of Amyotrophic Lateral Sclerosis/Frontotemporal Lobar Degeneration.CRISPR/Cas9-mediated targeted gene correction in amyotrophic lateral sclerosis patient iPSCs.Modelling amyotrophic lateral sclerosis: progress and possibilitiesInduced pluripotent stem cell: A headway in reprogramming with promising approach in regenerative biology
P2860
Q26269819-39F08D5B-4E94-41DC-9CA0-24C5863BE55DQ26269829-09CBA9CF-27A7-4317-A304-00BDE56C3AFBQ26753110-4FC7F31F-85DD-4469-8F63-CE6E5A5F8649Q26766372-A8EF63AA-6C2F-420D-AADE-1FAEED35B7DBQ26768144-99D4B28E-FD65-4894-9995-F4BCA641A5D6Q26771402-6DB80063-DFE9-403E-9F56-B559F3ADD72FQ26772307-A59766BF-DA28-4D47-B9D0-E97C5F7C6CFEQ26773168-9BEAEEB6-0DA5-4FB7-B71B-2BE11B75BF56Q26774824-86BBBE18-A502-4867-9EE6-D9998AC48E8BQ26775122-91D359BF-715A-431A-95FC-8B9FAC6341F4Q26783672-93FD4827-0DFC-4E03-AF43-DAC9173821A0Q26799285-5DADF96E-9F4A-4B47-B964-313C08BF1FACQ26799331-324C0ABA-4D19-4050-9F13-50806AD20898Q26801711-1188F351-E1D2-4106-9EB4-749FF492F89AQ26822437-CB5333A6-EAC6-484D-BDD6-2E394E913FD6Q26827806-8619D0DA-5DC6-415C-98D8-B089AA94B8C3Q26830425-34FA4439-C55C-4537-A694-07E9D0B1ABFBQ26863612-E1029504-A2F9-466C-A372-679012563488Q26998919-EC155380-BA7D-4997-A1E4-AF0C6354E74AQ27000647-94F90F93-1FC6-4537-97CC-A32F694A37DFQ27004209-82028E26-DBCF-44E9-B8B2-AC9A1AB46D5FQ27005360-FB109E84-A930-4A05-B6CB-441EE5F0E24AQ27025493-F62F1E56-8B7F-4E14-AB51-3C911D580911Q27303723-6F6B375A-A619-427A-952A-C451312AB3B3Q27305816-250FF6F7-9CAF-46DD-A389-32F6C6F15D9EQ27338320-0F68E747-0F6A-48EB-BF3A-0E9B9945E252Q28077853-CC028339-BBE4-46A2-A6B0-9EC65097F34AQ28080614-01FC3001-1EE7-42C7-9BDC-BA510323C370Q28081565-A0358FAB-AF34-431E-BB02-3E6D3C9E0600Q28082668-9D8E356D-2747-4638-943D-55AFEA27AFECQ28543975-3F31D2AB-8AEC-4DDB-A7A0-2142E39177ADQ28829196-767D44A4-7E66-474F-AE57-D1AB5E7B8A49Q30401824-95E0E858-9860-45D1-AEC8-248FE443D49FQ30537986-55528D0E-B2AB-4FCD-ACF8-D918D4515B6FQ30570770-65C452AA-E52C-4F78-80FD-E65B418E0097Q31140540-D5FB40E5-FADD-4764-82E5-8A0FC6E51B9BQ33586011-36F4788E-00AE-4FE1-AED9-A46E1F1E08F1Q33628110-907745BE-A200-4CD5-AD6A-191115B13508Q33746289-A958E170-5167-4240-8DEB-0F3093DED1AAQ33877155-5A6C0BA9-495A-4030-91A4-82844CB3F029
P2860
Drug screening for ALS using patient-specific induced pluripotent stem cells.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Drug screening for ALS using patient-specific induced pluripotent stem cells.
@en
Drug screening for ALS using patient-specific induced pluripotent stem cells.
@nl
type
label
Drug screening for ALS using patient-specific induced pluripotent stem cells.
@en
Drug screening for ALS using patient-specific induced pluripotent stem cells.
@nl
prefLabel
Drug screening for ALS using patient-specific induced pluripotent stem cells.
@en
Drug screening for ALS using patient-specific induced pluripotent stem cells.
@nl
P2093
P4510
P50
P921
P1476
Drug screening for ALS using patient-specific induced pluripotent stem cells.
@en
P2093
Akihiro Kawata
Akira Tamaoka
Akira Watanabe
Asuka Morizane
Dai Watanabe
Fred H Gage
Fumihiko Adachi
Haruhisa Inoue
Hidefumi Ito
Hiroshi Takuma
P304
P356
10.1126/SCITRANSLMED.3004052
P407
P577
2012-08-01T00:00:00Z